Tradestie Institutional Equity Comparison Engine
CLYM vs ENSC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CLYM Overall Edge
CLYM Captures Institutional Edge (2โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical while ENSC counters with relative strength in Valuation. Fundamentally, CLYM trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ENSC at 0.8x Forward P/E and -281.3% operating margin (-15.1% YoY). In options structure, CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ENSC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
ENSC
CLYM N/M vs ENSC 0.8x Fwd P/E
Growth & Margin Winner
CLYM
Op Margin 0.0% vs -281.3% ยท YoY +0.0% vs -15.1%
Momentum & Technical Winner
CLYM
1Y +399.5% vs -80.3% ยท 52W Pos 45% vs 8%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLYM
NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.19
-0.97% 1D
Market Cap
$545.1M
1M Return
-12.81%
1Y Return
+399.46%
Forward P/E
N/M
Unified AI Score
43.7 / 100
HOLD
Tech 40.0
Fund 54.0
Flow 50.0
Mom 54.0
ENSC
NASDAQ
Ensysce Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$0.36
-0.17% 1D
Market Cap
$7.0M
1M Return
-29.55%
1Y Return
-80.33%
Forward P/E
0.8x
Unified AI Score
53.4 / 100
HOLD
Tech 50.0
Fund 62.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CLYM +399.46%
ENSC -80.33%
Spread: +479.79 pp (CLYM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CLYM TTM Op. Margin: 0.0%
ENSC TTM Op. Margin: -281.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs ENSC. Trailing 12-month operating profitability (CLYM 0.0% vs ENSC -281.3%) and valuation multiples (CLYM N/M vs ENSC 0.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CLYM | ENSC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $545.1M | $7.0M | Larger Scale | CLYM |
| Trailing P/E Ratio Valuation | N/M | 0.8x | Lower Multiple | ENSC |
| Forward P/E Ratio Valuation | N/M | 0.8x | Lower Multiple | ENSC |
| Revenue Growth (YoY) Growth | +0.0% | -15.1% | Higher Growth | CLYM |
| Operating Margin (TTM) Profitability | 0.0% | -281.3% | Higher Margin | CLYM |
| Net Profit Margin Profitability | 0.0% | -280.5% | Higher Margin | CLYM |
| Return on Equity (ROE) Capital Efficiency | -29.3% | -1295.1% | Higher ROE | CLYM |
| 52-Week Range Position Momentum | 45% ($2โ$18) | 8% ($0โ$2) | Stronger Trend | CLYM |
| Beta / 30D Volatility Risk Regime | 1.42ฮฒ ยท 106% Vol | 0.98ฮฒ ยท 79% Vol | Lower Realized Risk | ENSC |
| Unified Institutional Score Composite Signal | 43.7 / 100 (HOLD) | 53.4 / 100 (HOLD) | Higher Composite | ENSC |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CLYM vs ENSC Buy Guide
CLYM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ENSC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CLYM nor ENSC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.